Get the Stockscreener App
10.46
7.52%
-0.85
After Hours:
10.46
Nurix Therapeutics Inc stock is traded at $10.46, with a volume of 842.57K.
It is down -7.52% in the last 24 hours and down -17.83% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$11.31
Open:
$11.2
24h Volume:
842.57K
Relative Volume:
1.00
Market Cap:
$799.66M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.6194
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-11.95%
1M Performance:
-17.83%
6M Performance:
-45.06%
1Y Performance:
-50.64%
1-Day Range:
$10.37
$11.32
1-Week Range:
$10.37
$11.67
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
10.46 | 864.64M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Victory Capital Management Inc. - MarketBeat
Equity Inducement as a Growth Engine: How Nurix Therapeutics Aligns Talent and Shareholder Value in Biotech Innovation - AInvest
What makes Nurix Therapeutics Inc. stock price move sharplyGet exclusive market analysis for investors - Jammu Links News
Is Nurix Therapeutics Inc. stock overvalued or undervaluedUnstoppable investment returns - Jammu Links News
Nurix Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Jammu Links News
Why is Nurix Therapeutics Inc. stock attracting strong analyst attentionHigh-yield portfolio picks - Jammu Links News
How many analysts rate Nurix Therapeutics Inc. as a “Buy”Access high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Nurix Therapeutics Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - Jammu Links News
What are Nurix Therapeutics Inc. company’s key revenue driversUnlock powerful trading signals for profits - Jammu Links News
Is it the right time to buy Nurix Therapeutics Inc. stockDiscover high-impact investment opportunities - Jammu Links News
Houte Hans Van Sells 5,402 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 4.9%Time to Buy? - MarketBeat
When is Nurix Therapeutics Inc. stock expected to show significant growthAdvanced Screener Data Feed To Watch Now - Jammu Links News
Nurix Therapeutics CFO Hans van Houte sells 5402 shares at $11.03 per share. - AInvest
Oppenheimer Reiterates "Outperform" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock - MarketBeat
Oppenheimer Reiterates Outperform Rating for Nurix Therapeutics (NRIX) | NRIX Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX) - GuruFocus
Will Nurix Therapeutics Inc. benefit from macro trendsGrowth Focused Entry Plan Suggestions Issued - metal.it
ARK Investment Management LLC Has $18.90 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Real time social sentiment graph for Nurix Therapeutics Inc.Profit Focused Stock Screener Results Released - metal.it
Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock By Investing.com - Investing.com India
Nurix Therapeutics CFO van Houte sells $51,695 in shares By Investing.com - Investing.com India
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock - Investing.com
Nurix Therapeutics CFO van Houte sells $51,695 in shares - Investing.com
Nikko Asset Management Americas Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Will Nurix Therapeutics Inc. Hold Gains Into CloseMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Does Nurix Therapeutics Inc. stock pay reliable dividendsAI Trading Suggestions With Accuracy Focus Released - metal.it
Y Intercept Hong Kong Ltd Invests $374,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
New York State Common Retirement Fund Boosts Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
NRIX Stock Price and Chart — NASDAQ:NRIX - TradingView
Nurix Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Does Nurix Therapeutics Inc. stock perform well during market downturnsFree Stock Selection - Jammu Links News
How does Nurix Therapeutics Inc. generate profit in a changing economyAccelerated investment success - Jammu Links News
Massachusetts Financial Services Co. MA Has $511,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
What drives Nurix Therapeutics Inc. stock priceTremendous financial leverage - printweek.in
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
Is Nurix Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):